PRNewsWire
18 Oct 2025, 14:00 UTC · 48w ago
Verdict
Headline takes no side. We score MLTX −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
MoonLake Immunotherapeutics' Phase 3 VELA trials for sonelokimab yielded disappointing results, with one trial failing its primary endpoint and the other showing only modest gains.
So whatThe failure of Phase 3 trials for a primary drug candidate typically destroys a biotech's valuation and core growth thesis.
More negative than 99% of claims this week
MoonLake's stock price plummeted 89.93% to $6.24 per share following the Phase 3 trial results.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
Pomerantz LLP is investigating MoonLake Immunotherapeutics and its officers for potential securities fraud or unlawful business practices.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud investigation following a 90% stock price crash due to disappointing Phase 3 trial results.
More negative than 85% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 85% of ticker scores this week
The company is being investigated by Pomerantz LLP for claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
+41.4%
Price is moving against the score
$12.90 vs $9.12 close before publication (Oct 17) · not market-adjusted
MLTX chart →
